Impact of baseline renal function on the efficacy and safety of different Anticoagulants in Atrial Fibrillation Patients – A cohort study

Table 1 Baseline characteristics of whole study group

Variables	Warfarin	DOAC				P value (Warfarin vs. DOAC)	P value
Variables		Dabigatran	Rivaroxaban	Apixaban	Edoxaban	P value (Warfarin vs. DOAC)	(4 DOACs)
*Number*	2189	1444	2461	958	472
*Gender (male)*	1175 (53.68)	900 (62.33)	1455 (59.12)	583 (60.86)	297 (62.92)	< 0.01	0.16
*Age (years)*	64.67 (11.94)	69.79 (9.93) ^a	70.44 (9.69) ^a	71.12 (9.94) ^a	70.36 (10.04) ^b	< 0.01	0.01
*Comorbidities*
Type 2 DM (%)	418 (19.10)	333 (23.06)	602 (24.46)	240 (25.05)	114 (24.15)	< 0.01	0.68
Hypertension (%)	1014 (46.32)	843 (58.38) ^a	1521 (61.80) ^a	617 (64.41) ^b	295 (62.50) ^a	< 0.01	0.02
Hyperlipidemia (%)	483 (22.06)	413 (28.60)	716 (29.09)	320 (33.40)	144 (30.51)	< 0.01	0.05
Heart failure (%)	635 (29.01)	269 (18.63)	534 (21.70)	200 (20.88)	91 (19.28)	< 0.01	0.12
Prior stroke (%)	226 (10.32)	222 (15.37) ^a	272 (11.05) ^b	81 (8.46) ^b	28 (5.93) ^c	< 0.01	< 0.01
Vascular disease (%)	50 (2.28)	36 (2.49) ^a	72 (2.93) ^a	60 (6.26) ^b	23 (4.87) ^b	< 0.01	< 0.01
*Renal function*
Serum Cr (mg/dL)	1.01 (0.33)	0.98 (0.27) ^a	1.00 (0.29) ^a	1.05 (0.35) ^b	1.04 (0.31) ^b	< 0.01	< 0.01
Baseline CrCl (mL/min)	68.55 (27.74)	67.73 (25.95) ^a	65.15 (24.32) ^b	62.5 (24.08) ^c	63.63 (23.84) ^c	< 0.01	< 0.01
*CHA2DS2-VASc score*	2.38 (1.53)	2.76 (1.50)	2.84 (1.51)	2.87 (1.44)	2.73 (1.52)	< 0.01	0.15
*HAS-BLED score*	1.36 (1.05)	1.65 (0.92) ^a	1.72 (0.93) ^a	1.78 (0.92) ^a	1.70 (0.97) ^b	< 0.01	< 0.01

Data are expressed as mean (standard deviation) or median (interquartile range) or as a number (percentage)
Different letters (a, b, c) associated with different groups indicate significant difference (at 0.05 level) by Bonferroni multiple comparison procedure

ISSN: 1477-9560